Australian Precision Medicine Enterprise
Accelerating precision medicine research
A precision medicine manufacturing, research, and innovation centre to advance diagnoses and treatments for cancer, cardiovascular, and neurological diseases is being developed at the Monash Biomedical Imaging site in Clayton.
Featuring a high energy cyclotron, the Australian Precision Medicine Enterprise (APME) will combine R&D, clinical trials and commercial manufacturing of advanced diagnostics and therapeutics in one world-class facility.
Due for completion in 2025, Monash Biomedical Imaging, together with its partners Global Medical Solutions (GMS) and Telix Pharmaceuticals, was successful in securing a $23M Modern Manufacturing Initiative grant for the $71M APME project.
Situated in the heart of the Monash Technology Precinct, the APME will be located on the Monash Biomedical Imaging site in Clayton, opposite the Victorian Heart Hospital. This strategic co-location will facilitate radiochemistry, PET and SPECT research and clinical use of thernanostic (therapeutic and diagnostic) radioisotopes produced on-site.
Locally produced radiopharmaceuticals
The research dedicated production part of the facility will initially produce radiometal labelled radiopharmaceuticals (copper-64, zirconium-89, gallium-68) using Good Manufacturing Practice (GMP) standards. Currently, there is no domestic GMP production capability for these radiopharmaceuticals for late-stage clinical research studies.
The local supply of GMP compliant radiopharmaceuticals will establish a sovereign capability for researchers, pharmaceutical companies, and the healthcare sector to accelerate the development, translation and availability of novel nuclear medicines for the diagnosis and eventually treatment of cancer, cardiovascular, neurological and other diseases in Australia.
To learn more about the importance of developing an Australian radiopharmaceutical industry, read the Australasian Association of Nuclear Medicine Specialists (AANMS) and the Australian and New Zealand Society for Nuclear Medicine (ANZSNM) submission to the House of Representatives.